Correction to: The best drug supplement for obesity treatment: a systematic review and network meta-analysis
Diabetology & Metabolic Syndrome volume 14, Article number: 68 (2022)
Correction to: Diabetol Metab Syndr (2021) 13:110 https://doi.org/10.1186/s13098-021-00733-5
Following publication of the original article , the Table 2 reports incorrect data for some of the studies included in the analysis:
In the study by Davies et al. (row 3), the dose of liraglutide should read 3.0 mg instead of 0.3 mg.
In the study by Greenway et al. (row 6), it should read Naltrexone 16.0 mg + bupropion instead of Naltrexone + bupropion 16.0 mg, and Naltrexone 32.0 mg + bupropion instead of Naltrexone + bupropion 32.0 mg.
In the study by O’Neil et al. (row 9) it should read Lorcaserin 10 mg BID instead of Orlistat 120.mg BID, and Lorcaserin 10 mg QD instead of Orlistat 120.mg QD.
Salari N, Jafari S, Darvishi N, Valipour E, Mohammadi M, Mansouri K, Shohaimi S. The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetol Metab Syndr. 2021;13:110. https://doi.org/10.1186/s13098-021-00733-5.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The article to which this update relates has been retracted. Please see the retraction notice for more detail: https://doi.org/10.1186/s13098-023-01048-3
About this article
Cite this article
Salari, N., Jafari, S., Darvishi, N. et al. Correction to: The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetol Metab Syndr 14, 68 (2022). https://doi.org/10.1186/s13098-022-00838-5